Literature DB >> 2121768

Immunochemical analysis of the alpha-subunit of the stimulatory G-protein of adenylyl cyclase in patients with Albright's hereditary osteodystrophy.

J L Patten1, M A Levine.   

Abstract

Albright's hereditary osteodystrophy (AHO) is an autosomal dominant disorder characterized by an unusual phenotypic appearance and reduced biological activity of the alpha-subunit of the stimulatory G-protein of adenylyl cyclase (Gs alpha). In most AHO patients deficient Gs alpha activity is associated with generalized target organ resistance to hormones that act via stimulation of adenylyl cyclase. This form of the disorder is termed pseudohypoparathyroidism type Ia (PHP Ia). By contrast, other patients with Gs alpha deficiency fail to demonstrate clinical evidence of hormone resistance and are considered to have the related disorder pseudopseudohypoparathyroidism (pseudoPHP). Previous studies demonstrating deficient Gs alpha bioactivity in cell membranes from patients with AHO used functional assays that were unable to distinguish between reduced amounts of normal Gs alpha protein and normal amounts of defective Gs alpha protein. In the present study we used specific Gs alpha antisera to analyze immunoactive Gs alpha protein in erythrocyte and fibroblast membranes from 20 patients with AHO who had either normal or reduced levels of Gs alpha mRNA. Cell membranes were subjected to immunoblot analysis using Gs alpha antisera developed against synthetic peptides corresponding to amino acid sequences in the amino- or carboxyl-terminus of the Gs alpha molecule. Fibroblast membranes from patients with AHO who had reduced or normal levels of Gs alpha mRNA contained both the 45- and 52-kDa forms of the Gs alpha protein in quantities that were significantly less [mean +/- SE, 52 +/- 6%; (n = 8) for reduced mRNA and 35 +/- 19% (n = 2) for normal mRNA, percentage of control values] than those present in membranes from normal subjects. Similar reductions were found in the level of the 45-kDa form of Gs alpha in erythrocyte membranes from all AHO patients studied [40 +/- 4% (mean +/- SE) of control values]. No abnormal forms of Gs alpha protein were detected. Cell membranes from patients with PHP type Ia and from patients with pseudoPHP contained levels of immunoactive Gs alpha that were equivalently reduced (43 +/- 4% vs. 42 +/- 5%, respectively). By contrast, erythrocyte membranes from patients with PHP type Ib, who have normal Gs alpha activity, had normal levels of Gs alpha immunoactivity (101 +/- 7%). These results indicate that most patients with AHO have reduced levels of Gs alpha protein as the basis for deficient Gs alpha bioactivity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121768     DOI: 10.1210/jcem-71-5-1208

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Mutations of signal-transducing G proteins in human disease.

Authors:  P Schnabel; M Böhm
Journal:  J Mol Med (Berl)       Date:  1995-05       Impact factor: 4.599

2.  Platelet signal transduction defect with Galpha subunit dysfunction and diminished Galphaq in a patient with abnormal platelet responses.

Authors:  J Gabbeta; X Yang; M A Kowalska; L Sun; N Dhanasekaran; A K Rao
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

3.  Polymorphism of the gene encoding the alpha subunit of the stimulatory G-protein of adenylyl cyclase (GNAS1).

Authors:  C Waltman; M A Levine; W F Schwindinger; G S Wand
Journal:  Hum Genet       Date:  1994-04       Impact factor: 4.132

4.  Differential expression of guanosine triphosphate binding proteins in men at high and low risk for the future development of alcoholism.

Authors:  G S Wand; C Waltman; C S Martin; M E McCaul; M A Levine; D Wolfgang
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

5.  Overexpression of stimulatory G protein alpha-subunit is a hallmark of most human somatotrophic pituitary tumours and is associated with resistance to GH-releasing hormone.

Authors:  C Hamacher; M Bröcker; E F Adams; T Lei; R Fahlbusch; M Buchfelder; M Derwahl
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

6.  Defective guanyl nucleotide-binding protein beta gamma subunits in a forskolin-resistant mutant of the Y1 adrenocortical cell line.

Authors:  J Mitchell; J K Northup; B P Schimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

7.  Pseudohypoparathyroidism type Ia: two new heterozygous frameshift mutations in exons 5 and 10 of the Gs alpha gene.

Authors:  H Shapira; M Mouallem; M S Shapiro; Y Weisman; Z Farfel
Journal:  Hum Genet       Date:  1996-01       Impact factor: 4.132

Review 8.  Current Nomenclature of Pseudohypoparathyroidism: Inactivating Parathyroid Hormone/Parathyroid Hormone-Related Protein Signaling Disorder.

Authors:  Serap Turan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-12-27

9.  The GNAS Locus: Quintessential Complex Gene Encoding Gsalpha, XLalphas, and other Imprinted Transcripts.

Authors:  Murat Bastepe
Journal:  Curr Genomics       Date:  2007-09       Impact factor: 2.236

Review 10.  DNA Methylation in the Diagnosis of Monogenic Diseases.

Authors:  Flavia Cerrato; Angela Sparago; Francesca Ariani; Fulvia Brugnoletti; Luciano Calzari; Fabio Coppedè; Alessandro De Luca; Cristina Gervasini; Emiliano Giardina; Fiorella Gurrieri; Cristiana Lo Nigro; Giuseppe Merla; Monica Miozzo; Silvia Russo; Eugenio Sangiorgi; Silvia M Sirchia; Gabriella Maria Squeo; Silvia Tabano; Elisabetta Tabolacci; Isabella Torrente; Maurizio Genuardi; Giovanni Neri; Andrea Riccio
Journal:  Genes (Basel)       Date:  2020-03-26       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.